

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (original) A derivative between hyaluronic acid and at least one heterocyclic compound derived from purine and/or from pyrimidine, said derivative being provided with at least one bond of a ionic type between said acid and said at least one heterocyclic compound.
2. (original) The derivative according to Claim 1, characterized in that said hyaluronic acid is hyaluronic acid of high molecular weight.
3. (original) The derivative according to Claim 2, characterized in that said hyaluronic acid has a molecular weight of between 400 000 and 4 million dalton.
4. (original) The derivative according to Claim 3, characterized in that said hyaluronic acid has a molecular weight of between 800 000 and 3.5 million dalton.
5. (original) The derivative according to Claim 4, characterized in that said hyaluronic acid has a molecular weight of between 1.5 and 3 million dalton.

6. (original) The derivative according to Claim 1, characterized in that said hyaluronic acid is hyaluronic acid of low molecular weight.

7. (original) The derivative according to Claim 1, characterized in that said heterocyclic compound is chosen between: adenine, guanine, thymine, cytosine, uracyl, 5,6 dihydrouracyl, 1-methyluracyl, 3-methyluracyl, 5-hydroxymethyluracyl, 2- thiouracyl, N<sup>4</sup>-acetylcytosine, 3-methylcytosine, 5-methylcytosine, 5- hydroxymethylcytosine, 1-methyladenine, 2-methyladenine, 7-methyladenine, N<sup>6</sup>-methliyladenine, N<sup>6</sup>, N<sup>6</sup>-dimethyladenine, N<sup>6</sup>-( $\Delta^2$ -isopentenyl)adenine, 1-methylguanine, 7-methylguanine, N<sup>2</sup>-methylguanine, and N<sup>2</sup>, N<sup>2</sup>-dimethylguanine.

8. (original) The derivative according to Claim 1, characterized in that said heterocyclic compound is chosen from between adenine, guanine, thymine, cytosine.

9. (currently amended) The derivative according to ~~Claims 1 and 7~~ Claim 1, characterized in that said bond of a ionic type is obtained between said acid and at least two of said heterocyclic compounds that are the same as or different from one another.

10. (currently amended) The derivative according to ~~Claims 1 and 7~~ Claim 1, characterized in that it is guanine hyaluronate.

11. (currently amended) The derivative according to ~~Claims 1 and 7~~ Claim 1, characterized in that it is adenine hyaluronate.

12. (original) The derivative according to Claim 1, characterized in that it is associated to at least one different organic compound.

13. (original) The derivative according to Claim 12, characterized in that said organic compound is chosen from between natural amino acids, their oligomers and polymers (peptides).

14. (original) The derivative according to Claim 13, characterized in that it is guanine hyaluronate, polylysine.

15. (original) The derivative according to Claim 13, characterized in that it is adenine hyaluronate, polylysine.

16. (original) The derivative according to Claim 1, characterized in that it is cross-linked.

17. (original) The derivative according to Claim 16, characterized in that said cross-linking involves at least one hydroxyl group and/or at least one carboxyl group present on said hyaluronic acid.

18. (original) The derivative according to Claim 16, characterized in that said cross-linking is obtained with phosgene.

19. (original) A process for the preparation of a derivative between hyaluronic acid and at least one heterocyclic compound according to Claim 1, characterized in that hyaluronic acid or a salt thereof is set to react with at least one heterocyclic compound in free or salified form.

20. (original) The process for the preparation of a derivative according to Claim 12, characterized in that said derivative of hyaluronic acid or a salt thereof is set to react with at least one organic compound in free or salified form.

21. (original) Use of a derivative according to Claim 1 in the cosmetic field.

22. (original) Use of a derivative according to Claim 1 in the pharmaceutical field.

23. (original) Cosmetic or pharmaceutical compositions comprising the compounds referred to in Claim 1.

24. (original) Cosmetic or pharmaceutical compositions comprising the compounds referred to in Claim 12.

25. (currently amended) Use of the compositions referred to in ~~Claims 23 and 24~~  
Claim 23 in the cosmetic and/or pharmaceutical field.